Meningioma: How social factors and personal risks relate to health outcomes
Official title: An Investigation of Tumor Genomics, Individual Risk Factors, and External Drivers of Health to Improve Health Outcomes for Patients With Meningioma
Run by University of California, San Francisco · NCT07418775 · Data updated 2026-11-12
This study tests whether social and personal risk factors help explain differences in health outcomes for adults with meningioma.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 3000 (estimated) |
| Sponsor | University of California, San Francisco Academic / other |
| Locations | 1 site (San Francisco, California) |
| Status | Recruiting |
| Started | January 16, 2026 |
| Main results expected | January 1, 2031 |
| Study ends | January 1, 2032 |
| Registry record updated | May 19, 2026 |
| Trial ID | NCT07418775 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 and older with a diagnosed meningioma who can read and speak English and can provide consent.
✕Probably not a fit
Patients who do not identify with the studied social determinants of health factors or whose conditions do not relate to the topics surveyed may see no direct benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study collects survey data from adults with meningioma and reviews their medical records to explore how social determinants of health and individual risk factors are distributed and may relate to outcomes. Researchers will examine disparities across racial groups and how factors such as access to care, environment, and personal health history correlate with disease experience. The study does not involve an intervention and uses surveys alongside medical record reviews to identify patterns and potential inequities. Participants are adults 18 years or older who can read English and have a meningioma. The lead sponsor is UCSF, with collaboration from the NCI, and the study is conducted at UCSF in San Francisco.
Why it matters
Potential benefit: Findings could illuminate inequities and inform strategies to improve care for diverse meningioma patients.
How similar studies have gone: Previous observational work on health disparities has demonstrated useful insights, though this exact combination of SSDH and meningioma is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults ≥18 years of age * Able to speak and read English * Diagnosed with a meningioma Exclusion Criteria: * Active psychiatric issues (suicidality, active psychosis, grave disability, etc.) * Inability to consent secondary to severe neurologic deficit or psychiatric distress * Inability to complete survey secondary to severe neurologic deficit or psychiatric distress
Where it's running
-
University of California San Francisco
San Francisco, California, United States Recruiting
Study contacts
- Principal investigator: David Raleigh, MD, PhD — University of California, San Francisco, San Francisco, California 94143
- Study coordinator: Zora Arum
- Email: zora.arum2@ucsf.edu
- Phone: 877-827-3222
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Home-based self-management and cognitive training for brain tumor survivors
This trial will try a home-based cognitive coaching program to see if it improves thinking and quality of life for adults who survived non-glioblastoma brain tumors, with optional caregiver participation.
-
Combining TIL Therapy and Pembrolizumab for Advanced Brain Cancer
This study is testing a new treatment that combines a type of immune therapy using patients' own tumor cells with Pembrolizumab to see if it helps people with advanced brain cancer feel better and live longer.
-
Impact of Radiotherapy on Neurocognition in Brain Tumor Patients
This study is testing how radiotherapy affects thinking and memory in adults with brain tumors over time to see if certain treatments lead to cognitive decline.
-
One-day exercise test to see how brain and body react in epilepsy, cognitive disorders, Parkinson's, dementia, and related conditions
A one-day study tests how an acute bout of exercise changes brain function and bodily signals in people with certain neurological conditions compared with healthy individuals.
-
Maintenance radiotherapy after standard glioblastoma treatment
This study tests whether a single 2 Gy maintenance radiotherapy dose after standard treatment is safe and feasible for adults with newly diagnosed glioblastoma.
-
BCB-276 CAR T therapy for DIPG in children and young adults
This study tests BCB-276, a patient's own CAR T cells against DIPG, after standard radiation, to see if it is safe and can help extend survival.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.